Ratings IRADIMED CORPORATION

Equities

IRMD

US46266A1097

Market Closed - Nasdaq Other stock markets 01:30:00 15/05/2024 am IST			5-day change	1st Jan Change
42.29 ^USD	-0.38%		-3.20%	-10.91%

02/05	Transcript : IRADIMED CORPORATION, Q1 2024 Earnings Call, May 02, 2024
02/05	Earnings Flash (IRMD) IRADIMED CORPORATION Posts Q1 Revenue $17.6M	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.42 times its estimated earnings per share for the ongoing year.
For the past year, analysts have significantly revised downwards their profit estimates.
The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
IRADIMED CORPORATION	-10.91%	538M	D+
SHOCKWAVE MEDICAL, INC.	+73.70%	12.4B	B-
PENUMBRA, INC.	-17.02%	7.94B	C+
MASIMO CORPORATION	-1.68%	6.17B	C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+16.74%	5.55B	D+
GETINGE AB	-3.21%	5.35B	B
APT MEDICAL INC.	+46.20%	5.03B	-
ASAHI INTECC CO., LTD.	-16.44%	4.07B	B-
INARI MEDICAL, INC.	-29.91%	2.65B	C
SKAN GROUP AG	-0.74%	1.99B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes